Form4insider filings, from the source

SEC Form 3 · accession 0001358403-19-000010

BELLICUM PHARMACEUTICALS, INC · BLCM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Rosemary Y. Williams
Officer — Principal Accounting Officer
Period of report
Aug 16, 2018
Accepted (ET)
Jan 4, 2019 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———3,186D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F1$2.55holding————Apr 30, 2024Common Stock17,647—D
Stock Option (right to buy)F2$7.47holding————Oct 27, 2024Common Stock11,764—D
Stock Option (right to buy)F3$23.47holding————Feb 23, 2025Common Stock14,000—D
Stock Option (right to buy)F4$19.00holding————Jan 3, 2026Common Stock15,000—D
Stock Option (right to buy)F5$13.89holding————Jan 2, 2027Common Stock5,625—D
Stock Option (right to buy)F6$11.70holding————Jul 2, 2027Common Stock13,125—D
Stock Option (right to buy)F7$9.23holding————Jan 1, 2028Common Stock9,225—D
Stock Option (right to buy)F8$7.72holding————Jul 1, 2028Common Stock21,525—D
Restricted Stock UnitsF10,F9—holding—————Common Stock2,344—D
Restricted Stock UnitsF10,F11—holding—————Common Stock5,125—D

Explanation of responses